Patent ID: 8536120

Claim:
A compound having a formula: A 1 -A 2 ′-A 3 ′-A 4 -A 5 -A 6 , wherein A 1 is His, Tyr, desamino Tyr, D Ala, β-Ala, CyclohexylAla (Cyclohexylalanine), DArg, Ava (aminovaleric acid), Gly, <Glu (pyroglutamic acid), αAib (alpha-aminoisobutyric acid), γAbu (gamma-aminobutyric acid), αAbu (alpha-aminobutyric acid), α,γAbu (alpha, gamma-diaminobutyric acid or 2,4-diaminobutyric acid), DVal, DPhe, DThr, DPal (pyridylalanine), DLys, AcDLys, DLeu, DTrp, Dβnaphthylalanine or AcDβnaphthylalanine, wherein the A 1 residue is with or without methylation of the terminal nitrogen of the α carbon atom of the A 1 residue when a terminal nitrogen is present at the α carbon atom, and wherein the peptide bond between the A 1 and A 2 ′ residues is a normal or reduced psi (Ψ, CH 2 NH) peptide bond; A 2 ′ is Dα or Dβnaphthylalanine, Trp, D or L Phe, Ala, His, PicLys, DCyclohexylalanine, D-4-halo-Phe or D-4-pyrolidylalanine, wherein A 2 ′ is with or without methylation of the terminal nitrogen of the α carbon atom of the A 2 ′ residue; A 3 ′ is D or L Lys, lysine derivatives, Orn, Phe, Trp, Leu, Pro, Ser, Pal, or α,γAbu; A 4 is D or L Trp, Phe, Ala, Ser, Tyr, Met, Pro, Thr, ILys, or CyclohexylAla; A 5 is D or L Trp, D or LPhe, Ala, Lys, Arg, Orn, Thr, Leu, or DCyclohexylAla; and A 6 is Lys, Arg, Orn, D or L Phe, Pro, Nle (norleucine), or α,γAbu; or prodrugs or pharmaceutically acceptable salts thereof, wherein the A 6 residue can be present either in a C terminal amidated form or as a free carboxylic acid.